Drug Psychiatry

Rexulti

Payments companies reported to CMS as associated with Rexulti. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$33Massociated payments (2023-2025)

90,875clinicians with associated payments

5companies reporting

By year

2023 $10M

2024 $11M

2025 $11M

Payments reported as associated with Rexulti, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Psychiatry $15M

Psychiatric/Mental Health (Nurse Practitioner) $4.9M

Family $2.1M

Internal Medicine $1.8M

Family Medicine $1.6M

Physician Assistant $1.3M

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Rexulti

These are the largest totals companies reported as associated with Rexulti. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Hassan Malik	Akron, OH	Internal Medicine	$516,610.08
Leslie Citrome	Pomona, NY	Psychiatry	$376,585.57
Rakesh Jain	Lake Jackson, TX	Psychiatry	$334,098.14
Mary Moller	Tacoma, WA	Psychiatric/Mental Health, Adult (Clinical Nurse Specialist)	$325,332.04
Amita Patel	Dayton, OH	Psychiatry	$313,235.35
Charles Tuan-Tu Nguyen	Irvine, CA	Psychiatry	$285,011.94
Georgia Stevens	Washington, DC	Psychiatric/Mental Health, Adult (Registered Nurse)	$280,256.03
Fred Romeo	Columbus, OH	Psychiatry	$269,431.55
Tad Tillemans	Little Rock, AR	Psychiatry	$268,701.86
George Grossberg	Saint Louis, MO	Psychiatry	$256,839.57

Prescribed Rexulti?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.